reduces quality of life. 1, 2 Care of these terminally ill patients is challenging and must incorporate an understanding of the quality and quantity of life remaining, overall patient health, success and morbidity of treatment options, and goals of patient care. to that end, there has been little been little systematic research on the incidence and risk factors of Bo in the advanced cancer patient; there has been no systemic study of the effectiveness of various treatment strategies to palliate Bo, which include surgical 3 and nonsurgical approaches, [4] [5] [6] [7] [8] [9] [10] [11] or of outcomes after hospital discharge. What little evidence exists to guide clinical decisions comes from small, single-institution studies, most single-armed, highly selective, and retrospective in nature. in part, because of this lack of clinical data, recommendations for treatment of patients with Bo stem from expert opinion 1 ; there is no consensus as to indications for 1 treatment over another, and no formal guidelines for the management of patients with Bo. 2, 12 We recently performed a population-based study of incidence and risk factors associated with hospitalization for Bo 13 in a cohort of patients with stage iV colon cancer with the use of the surveillance, epidemiology, and end Results (seeR)-medicare database. 14 among 12,553 patients with stage iV colon cancer, we identified 1004 (8.0%) who were hospitalized with Bo after cancer diagnosis. in this follow-up study, we examine the treatment patterns for Bo in these 1004 individuals. We report outcomes after hospitalization for Bo and examine survival experience after Bo in elderly patients with stage iV colon cancer.
METHODS

Data Source
We analyzed data from the seeR-medicare database. 14 the seeR database tracks patients with cancer in approximately 14% of the us population up to 1999, and 26% from 2000 forward. surveillance, epidemiology, and end Results database contains demographic information and records of tumor histology, location, stage, and survival. medicare provider review (medPaR) files summarize all services rendered to an inpatient hospital beneficiary from admission through discharge. Physician and outpatient billing files contain procedure and diagnosis codes for services rendered.
Cohort Selection
We used International Classification of Disease, 9th Revision (iCD-9) codes 15 to identify individuals >65 years with a pathologically confirmed first diagnosis of stage iV colon adenocarcinoma between January 1, 1991, and December 31, 2005, considering International Classification of Diseases for Oncology, 3rd Edition codes 814, 821, 822, 825, 826, 848, and 857 to indicate adenocarcinoma. study sub-jects with unknown month of diagnosis and those eligible for medicare for reasons other than age were excluded. We also excluded individuals enrolled in a health maintenance organization at any time from colon cancer diagnosis to death, because billing claims for these patients may not have been submitted to medicare for reimbursement.
Patient Characteristics
We extracted patient characteristics, including age, sex, race, marital status, month of cancer diagnosis, and tumor characteristics from seeR. age and comorbidity were calculated at the time of first hospitalization for obstruction; all other patient and tumor characteristics reflect conditions at cancer diagnosis. We categorized age in 5-year increments, and race as white, black, and other or unknown. We considered divorced, separated, single, and widowed subjects to be unmarried. Cancer diagnosis date was designated as the 15th day of the month of diagnosis. We classified tumors into proximal/right-sided (cecum, ascending colon, hepatic flexure, and transverse colon) and distal/left-sided (splenic flexure, descending, and sigmoid colon). tumors were classified by histology as mucinous (International Classification of Diseases for Oncology, 3rd Edition 848) or nonmucinous, and tumor grade as well/ moderately differentiated, poorly differentiated or undifferentiated, and unknown. Cases were grouped by nodal involvement into n0 (no lymph nodes involved by tumor), n1 (1-3 nodes involved), n2 (>3 nodes involved), and unknown according to american Joint Committee on Cancer staging criteria. 16 We categorized patients as having had primary tumor resection (PtR) if we found a medicare claim for colon resection within 6 months of diagnosis. if PtR was coincident with a claim for obstruction or perforation, we considered those conditions present at cancer diagnosis. We excluded patients with a history of Bo before cancer diagnosis. from the remaining cohort, we identified patients hospitalized at an acute-care hospital after cancer diagnosis in which a diagnosis code for Bo was used in a medPaR inpatient hospital claim (560.81, 560.89, 560.9). We further identified the subset of patients in whom the diagnosis code specific to adhesive Bo (560.81) was ever used in a medPaR claim ("ever-adhesive"). finally, we assessed patients' chemotherapy treatment from medPaR, physician, and outpatient claims files. 17
Assessment of Comorbid Disease
to assess the prevalence of comorbid disease at the time of obstruction, we used the Klabunde adaptation of the Charlson comorbidity index. 18 We weighted 19 health conditions identified by iCD-9 diagnosis codes in medicare inpatient and outpatient claims and calculated a composite score for each patient.
Characteristics of Surgical Treatment for BO
We extracted information on treatment of Bo by searching physician and hospital claims files for level ii healthcare Common Procedure Coding system (hCPCs): Current Procedural terminology and iCD-9 procedure codes. We considered a claim for gastroenterostomy or enteroenterostomy (iCD-9: 44. 3 23, 46.24; hCPCs: 44021, 44141, 44143, 44144, 44146, 44150, 44210, 44151, 44155, 44156, 44187, 44310, 44188, 44320, 44206, 44208, 44210, 44212, 44300, 44310, 44316, 44320) , and lysis of peritoneal adhesions (iCD-9: 54.5, 54.51; hCPCs: 44005, 44180) to represent surgical therapies. We did not consider a claim for laparotomy or laparoscopy to constitute surgical therapy in the absence of secondary procedure codes.
Outcomes
We used medPaR hospital claims to calculate length of stay, considering transfers to another acute care hospital as part of the same hospitalization. We considered any hospital claim that postdated the initial claim for obstruction to constitute readmission. We used medicare date of death to calculate days of life remaining after obstruction and the ratio of days in to days out of the hospital.
Statistical Analysis
associations between baseline demographic and clinical variables and surgical vs nonsurgical treatment of Bo were compared by the use of χ 2 tests. We compared differences in time to obstruction by using the mann-Whitney U test. We used Kaplan-meier curves to compare hospital length of stay and overall and postobstruction survival times. When presenting postobstruction survival curves, we adjusted for covariates by using the method described by Cole and hernán. 19 When we analyzed length of stay, patients dying in the hospital were censored; when we analyzed survival, patients alive at last follow-up were censored. among those deceased at last follow-up, we compared total days in and out of a hospital by using the mann-Whitney U test. We modeled survival after obstruction by using Cox proportional hazards models, and we used reverse stepwise regression to build a final model. We retained predictors significantly associated with survival and those whose removal changed parameter estimates by ≥10%. all statistical tests were 2-sided, and we considered a p value of <0.05 statistically significant. analyses were performed by using sas 9.2 statistical software (sas institute, Cary, nC).
RESULTS
We identified1004 patients hospitalized for Bo after diagnosis of stage iV colon adenocarcinoma between January 1, 1991 and December 31, 2005. of these patients, 281 (28.0%) received surgical treatment while hospitalized; the characteristics of the cohort with Bo, stratified by treatment type, are shown in table 1. those who received surgical vs nonsurgical therapy were similar for most characteristics, including age and comorbidity; tumor pathologic and treatment characteristics appeared similar as well. there was a reduction in the use of surgical therapy over time: 32.4% of Bos between 1991 and 1996 received surgical therapy in comparison with 25.2% from 1997 to 2001 and 26.6% from 2002 to 2006 (p for trend 0.088).
outcomes after hospitalization for Bo are shown in table 2. Patients were hospitalized approximately 1 week, and 12.7% died in the hospital. median survival after hospitalization for Bo was only 73 days among all patients; 6-month and 1-year survivals were 30% and 16%. of the 817 who survived the initial hospitalization and died during the follow-up period, 201 (24.6%) were readmitted to an inpatient facility with a diagnosis code for obstruction at least once before death. hospital length of stay was longer among patients treated surgically compared with those treated nonsurgically (11 vs 7 days, p < 0.001), although 30-day mortality was higher among those not receiving surgery during hospitalization for Bo (30.8% vs 18.5%, p = 0.003). the absolute difference in median survival between those treated surgically vs nonsurgically was 56 days; however, those receiving surgery spent more days in the hospital during the final period of life. ultimately, the ratio of time in to time out of the hospital was approximately 1:5 in both populations.
Patients who ever had a code for adhesive obstruction ("ever adhesive") comprised 16.3% (n = 164) of the obstructed cohort and accounted for 40.5% of surgically treated events. median survival was nearly 3 times longer than in the never adhesive group (179 vs 63 days, p < 0.001).
Predictors of Postobstruction Survival
a univariable Cox proportional hazards model of survival after hospitalization for obstruction is shown in table 3. in univariable analysis, surgical treatment of Bo was associated with longer postobstruction survival (hR 0.81, p = 0.003). the distinction of an "ever adhesive" obstruction was even more strongly related to favorable survival (hR 0.63 vs "never adhesive," p < 0.001). high tumor grade and high nodal stage were associated with worse postobstruction survival, whereas tumor histology was unrelated to survival. Receipt of chemotherapy both before (hR 0.78, p < 0.001) and after obstruction (hR 0.76, p < 0.001) increased postobstruction survival; nearly 98% of those receiving chemotherapy before Bo also received it after hospitalization. sex, race, marital status, comorbidity, and age at obstruction were unrelated to postobstruction survival. two multivariable Cox proportional hazards models are shown in table 4, differing based on the inclusion of an "ever adhesive" variable. in both models of postobstruction survival, receipt of chemotherapy, tumor grade and site, and node status remained important predictors of postobstruction survival, as did time elapsed between cancer diagnosis and hospitalization for obstruction (hR 0.99 for each month elapsed, p = 0.003). in the first model, which did not distinguish obstructions based on the appearance of billing codes indicating adhesive disease, surgical treatment of obstruction was associated with improved post-Bo survival (hR 0.80, p = 0.003). in the second model, which did distinguish obstructions by the use of adhesive obstruction codes, "ever adhesive" status was significantly associated with improved survival after hospitalization for obstruction (hR 0.67, 95% Ci: 0.56-0.81). in this model, surgical treatment of Bo was no longer a significant predictor of postobstruction survival (hR 0.91, 95% Ci: 0.77-1.06), whereas the relationships between survival and time elapsed between cancer diagnosis and obstruction, chemotherapy, and tumor grade, site, and node stage were essentially unchanged. adjusted survival curves comparing the surgical with nonsurgical and "ever adhesive" with "never adhesive" groups are shown in figures 1 and 2. in multivariable models PtR at diagnosis (p = 0.90) and year of hospitalization for obstruction (p = 0.217) were no longer associated with survival and were removed from the models.
DISCUSSION
We examined treatment and outcomes after hospitalization for Bo in 1004 patients in seeR-medicare diagnosed with stage iV colon cancer between 1991 and 2005.twenty-eight percent of patients were treated surgically for Bo, a trend that decreased over time. hospitalization for obstruction occurred a median of 7 months after cancer diagnosis, and median survival after obstruction was less than 3 months. treatment required about a week in the hospital, and 12.7% of patients admitted with obstruction died in the hospital. once discharged from the hospital, 60% of patients returned home; however, 25% were readmitted for obstruction at least once during the remaining months of life. During this terminal period, the overall ratio of days in the hospital to days out of the hospital was about 1:5 and did not differ by surgical vs nonsurgical treatment of Bo (p = 0.87). finally, when controlling for potential confounders, "ever adhesive" disease (hR 0.67, 95% Ci: 0.56-0.80) and receipt of chemotherapy at any time (hR 0.66, 95% Ci: 0.58-0.76) were favorably associated with post-Bo survival; however, surgical treatment of obstruction was not.
the median postobstruction survival of 73 days in this group is within the 2-to 7-month median range reported in previous hospital-based studies of Bo. [20] [21] [22] [23] [24] only 16% of our cohort was alive 1 year after hospitalization for Bo, which is also consistent with many retrospective series. 2, 20, 25 Retrospective series have also reported inhospital mortality rates of between 5% and 38% in patients treated operatively and nonoperatively for Bo, 26, 27 similar to our 12.7% in-hospital mortality and indicative of the nutrition depletion and debilitated functional status common in this population. 8 among those ultimately discharged from the hospital, life after hospitalization for Bo was care intensive: nearly one-quarter were readmitted with diagnostic codes for Bo between initial obstruction and death. this finding is consistent with reports on frequency of recurrence of obstructive symptoms after initial hospitalization, which ranged from 21% to 50%. 16, 22, [26] [27] [28] [29] although there are no formalized guidelines for treatment of Bo in the patient who has advanced cancer, 2,12 expert opinion suggests that surgical treatment should be undertaken only when a patient's estimated life expectancy is greater than 2 months. 25, 30, 31 additional contraindications to surgical therapy relate to the location, multifocality, and severity of obstruction, the presence of ascites or cachexia, and poor performance status 1 -factors that we are unable to capture in seeRmedicare. therefore, although we present outcomes stratified by treatment, these comparisons are unavoidably biased. Consistent with expected patient selection for invasive treatment, survival after obstruction was longer in the group treated surgically than in the group treated nonsurgically, although in-hospital mortality was higher. finally, the frequency of hospital readmission for Bo was lower in the group treated surgically, consistent with retrospective series arguing that surgery for Bo is more durable than medical management alone. 32 Despite slightly more favorable outcomes in this group, those treated surgically spent more time in-hospital for all causes during the postobstruction period; as a result, the ratio of time spent in the hospital during the terminal stage of disease was equivalent between treatment strategies, consistent with Chan and Woodruff. 23 finally, in a multivariable model including prognostic tumor characteristics, surgical treatment of Bo was not associated with prolonged survival.
We defined Bo with the use of both specific (560.81) and nonspecific iCD-9 diagnosis codes (560.89,560.9). the justification for including both coding schemes was, in part, based on evidence that the cause of Bo in patients with advanced cancer is not always apparent: 4 reports between 1969 and 1997 noted that 24% to 37% of obstructions in patients with previous cancer were attributable to new primary cancer or benign causes. 21, [26] [27] [28] 33 in these series, cause was predominantly determined by laparotomy, and only 28% of our study cohort underwent surgery. one of the aforementioned publications indicated that Ct scan was part of the workup of at least some patients, 27 and 1 radiology series has demonstrated that the cause of obstruction was accurately determined in 12 of 13 patients with malignant obstruction 34 ; however, other studies evaluating the predictive value of Ct in determining the cause of obstruction have included few patients with malignancy. 35, 36 Despite this difficulty in determining the cause of Bo nonoperatively, distinguishing these entities in patients with advanced cancer can be meaningful. a populationbased study of 32,583 patients admitted for Bo suggested that 75% of benign obstructions will resolve with medical therapy alone, 37 whereas retrospective studies indicate that nonoperative intervention is much less successful among patients with a history of malignancy (24%-32%). 26, 28, 29, 38 in series distinguishing benign from malignant causes of obstruction in patients with cancer, the prognosis after surgical treatment for benign obstruction is superior to survival after treatment of malignant obstruction. 21, 26 Consistent with these publications, we found that median postobstruction survival among patients with adhesive disease after cancer diagnosis ("ever adhesive") was 3 times longer than among "never adhesive" patients (179 vs 63 days, p < 0.001). although it is likely that some adhesive obstructions were misclassified as nonspecific and vice versa, we had no reason to believe that this misclassification would be differential by survival. thus, the survival benefit we observed may understate the true benefit associated with adhesive obstruction. although there were differences in prognosis based on the cause of obstruction, absolute survival after Bo was universally poor, consistent with the natural history of advanced colon cancer and similar to findings of an institutional series whose patient population closely resembled our own: among 62 surgically treated patients with colon cancer, predominantly with stages iii and iV disease, spears and colleagues 21 noted a median survival of only 6 months following surgery for benign obstructions vs 2 months when obstruction was secondary to malignancy, results that parallel our "ever adhesive" and "never adhesive" groups. our conclusions are strengthened by the populationbased and relatively large sample size provided by seeRmedicare. We were able to track 94% of patients from obstruction to death, enabling a deeper look into the postobstruction experience than previous hospital-based studies. We were also able to evaluate a nonselected cohort; previous studies have often reported only on patients treated surgically and have failed to include those not treated surgically or those whose operative interventions were unsuccessful. 2 there are several limitations to our study. owing to a lack of specific procedure codes, we were unable to assess the effectiveness of several nonsurgical therapeutic strategies. for instance, endoscopic stenting has emerged as an option to palliate Bo, 4-7 but we could not assess stenting because no specific International Classification of Diseases, Ninth Revision, Clinical Modification code for insertion of a colonic stent existed until 2009. 39 for similar reasons, we were unable to assess the use of octreotide. [8] [9] [10] [11] further, we could not determine the indication for the use of gastrostomy tubes (ie, decompression vs feeding), nor could we assess the effectiveness of nasogastric suctioning. most importantly, we were unable to assess the indications for surgery and, therefore, could not adjust treatment analysis for patient selection. finally, the use of seeR-medicare does not allow us to assess the success of various treatments in the palliation of obstructive symptoms, arguably the most important outcome in treating this disease, yet one that is rarely addressed in the literature. 2, 12 CONCLUSION our results suggest that Bo is a preterminal event and that patients should be informed that median survival under any treatment strategy is poor. the length and intensity of hospital care for Bo, and the possible need for readmission for obstruction, should be incorporated into medical decision making. in this setting, it appears that palliative approaches to care seeking to maximize the quality of remaining life are well justified.
